Charles River Laboratories Intl. Inc vs Carparts.Com Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $286.11 (market cap $13.46B), while Carparts.Com Inc trades at $6.34 (market cap $51.67M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 260.5× Carparts.Com Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Carparts.Com Inc nearer its low. Which is the better fit depends on your goals.
| CRL | PRTS | |
|---|---|---|
Market Cap | $13.46B | $51.67M |
Sector | Health | Consumer Cyclical |
52-Week High | $282.00 | $11.40 |
52-Week Low | $145.57 | $3.88 |
Enterprise Value | $16.30B | $66.64M |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.
The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.
CarParts.com (PRTS) trades at $6.32, down 6.37% today, with a bullish technical signal despite negative profitability metrics. The company has beaten earnings expectations for three consecutive quarters, though revenue has declined from $676M in 2023 to $548M in 2025. Recent developments include a 10:1 reverse stock split completed in May 2026 and a new $25M credit facility, while analyst consensus remains positive with 60% buy ratings.
The outlook is mixed: technical indicators and analyst sentiment suggest potential upside, but fundamental challenges persist with negative net income margins and cash flow concerns. Key risks include ongoing operational losses and competitive pressures in the auto parts e-commerce space, requiring careful monitoring of the company's turnaround execution.
Trailing returns across standard periods
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →